Literature DB >> 22760582

Myocardial recovery with left ventricular assist devices.

Maya Guglin1, Leslie Miller.   

Abstract

OPINION STATEMENT: Advanced heart failure (HF) is a condition that is rarely thought of in terms of cure. Left ventricular assist devices (LVADs), like no therapy before them, provide complete decongestion of the left ventricle, with resulting favorable changes at all levels, from reversal of hypertrophy of cardiomyocytes to recovery of normal geometry and function of the ventricles. Although not a frequent phenomenon at most institutions, LV recovery is achieved in 20-25 % of LVAD recipients in some programs. Patients with good chances for recovery are usually young, with nonischemic cardiomyopathy and short duration of HF symptoms. After LVAD removal, patients with recovered function remain asymptomatic for years. To reach this level of sustainable restoration of cardiac function, several steps need to be taken: 1) myocardial recovery has to be recognized as a therapeutic goal, especially in patients with nonischemic cardiomyopathy; 2) HF medications have to be restarted and aggressively uptitrated after LVAD implantation; 3) regular monitoring for signs of myocardial recovery (eg, echocardiography or hemodynamics) should become a standard practice in LVAD centers; and 4) weaning protocols should be discussed and accepted at each LVAD program. While some protocols involve extensive several-day testing both at rest and with exercise, others are mostly guided by echocardiographic evaluation.

Entities:  

Year:  2012        PMID: 22760582     DOI: 10.1007/s11936-012-0190-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  92 in total

1.  National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008.

Authors:  Jersey Chen; Sharon-Lise T Normand; Yun Wang; Harlan M Krumholz
Journal:  JAMA       Date:  2011-10-19       Impact factor: 56.272

2.  Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy?

Authors:  Goro Matsumiya; Osamu Monta; Norihide Fukushima; Yoshiki Sawa; Toshihiro Funatsu; Kouichi Toda; Hikaru Matsuda
Journal:  J Thorac Cardiovasc Surg       Date:  2005-09       Impact factor: 5.209

3.  Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics, and outcomes.

Authors:  Marc A Simon; Robert L Kormos; Srinivas Murali; Pradeep Nair; Michael Heffernan; John Gorcsan; Stephen Winowich; Dennis M McNamara
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

4.  Characterization of super-response to cardiac resynchronization therapy.

Authors:  John Rickard; Dharam J Kumbhani; Zoran Popovic; David Verhaert; Mahesh Manne; Daniel Sraow; Bryan Baranowski; David O Martin; Bruce D Lindsay; Richard A Grimm; Bruce L Wilkoff; Patrick Tchou
Journal:  Heart Rhythm       Date:  2010-04-08       Impact factor: 6.343

5.  Long-term follow-up on cardiac function following fulminant myocarditis requiring percutaneous extracorporeal cardiopulmonary support.

Authors:  Kohki Ishida; Hiroshi Wada; Kenichi Sakakura; Norifumi Kubo; Nahoko Ikeda; Yoshitaka Sugawara; Junya Ako; Shin-ichi Momomura
Journal:  Heart Vessels       Date:  2011-12-28       Impact factor: 2.037

6.  Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable ventricular assist device.

Authors:  S Nakatani; P M McCarthy; K Kottke-Marchant; H Harasaki; K B James; R M Savage; J D Thomas
Journal:  J Am Coll Cardiol       Date:  1996-03-15       Impact factor: 24.094

7.  Alterations in Ca2+ cycling proteins and G alpha q signaling after left ventricular assist device support in failing human hearts.

Authors:  Y Takeishi; T Jalili; B D Hoit; D L Kirkpatrick; L E Wagoner; W T Abraham; R A Walsh
Journal:  Cardiovasc Res       Date:  2000-03       Impact factor: 10.787

8.  Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery.

Authors:  G Torre-Amione; S J Stetson; K A Youker; J B Durand; B Radovancevic; R M Delgado; O H Frazier; M L Entman; G P Noon
Journal:  Circulation       Date:  1999-09-14       Impact factor: 29.690

9.  A novel percutaneous mechanical biventricular bridge to recovery in severe cardiac allograft rejection.

Authors:  Vivek Rajagopal; Gregg Steahr; Charles I Wilmer; Nirav Y Raval
Journal:  J Heart Lung Transplant       Date:  2010-01       Impact factor: 10.247

10.  Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes.

Authors:  M Petrou; D G Wynne; K R Boheler; M H Yacoub
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

View more
  2 in total

1.  Preoperative beta-blocker treatment is a key for deciding left ventricular assist device implantation strategy as a bridge to recovery.

Authors:  Teruhiko Imamura; Koichiro Kinugawa; Masaru Hatano; Takeo Fujino; Hironori Muraoka; Toshiro Inaba; Hisataka Maki; Yukie Kagami; Miyoko Endo; Osamu Kinoshita; Kan Nawata; Shunei Kyo; Minoru Ono
Journal:  J Artif Organs       Date:  2013-12-15       Impact factor: 1.731

2.  Targeted myocardial gene expression in failing hearts by RNA sequencing.

Authors:  Kajari Dhar; Alexandra M Moulton; Eric Rome; Fang Qiu; Jeff Kittrell; Eugenia Raichlin; Ronald Zolty; John Y Um; Michael J Moulton; Hesham Basma; Daniel R Anderson; James D Eudy; Brian D Lowes
Journal:  J Transl Med       Date:  2016-11-25       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.